Gillian Vandekerkhove
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gillian Vandekerkhove has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
102 shared publications - Cameron Herberts
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
96 shared publications - Bernhard J. Eigl
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
82 shared publications Matti Annala
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada
67 shared publicationsAmanda Wong
Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada
65 shared publications- Daniel J. Khalaf
BC Cancer Prostate Centre BC Cancer BC Cancer Prostate Centre Tulane University BC Cancer Arkhjamil Angeles BC Cancer Tulane University University of British Columbia University of British Columbia Tulane University Chi University of British Columbia
65 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-12 from Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Supplementary Figures 1-12 with embedded captions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-12 from Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Supplementary Figures 1-12 with embedded captions.
- Top Cited PapersOpen Access
- 27 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer
Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear. Here, in a prospective, multicentre study, we show that ctDNA testing has high concordance with tissue FGFR testing and identifies additional actionable FGFR alterations. We profile plasma from 208 patients with mUC undergoing clinical FGFR tissue testing for erdafitinib eligibility. In evaluable baseline samples, FGFR alteration frequency is 26% in either tissue or ctDNA. Among 125 patients with baseline detected ctDNA and paired tissue results, FGFR status is concordant in 90%, and ctDNA has an 84% sensitivity for tissue-detected alterations while also identifying 7 additional cases. Serial plasma collections post-baseline further clarify FGFR status. In 21 patients who received erdafitinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdafitinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.
- 27 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessProspective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer
Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear. Here, in a prospective, multicentre study, we show that ctDNA testing has high concordance with tissue FGFR testing and identifies additional actionable FGFR alterations. We profile plasma from 208 patients with mUC undergoing clinical FGFR tissue testing for erdafitinib eligibility. In evaluable baseline samples, FGFR alteration frequency is 26% in either tissue or ctDNA. Among 125 patients with baseline detected ctDNA and paired tissue results, FGFR status is concordant in 90%, and ctDNA has an 84% sensitivity for tissue-detected alterations while also identifying 7 additional cases. Serial plasma collections post-baseline further clarify FGFR status. In 21 patients who received erdafitinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdafitinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.
- Open Access
- 27 October 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (3) , 388-402
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
- 27 October 2025
- Published by Elsevier in Annals of Oncology
- Vol. 37 (3) , 388-402
Open AccessRepertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 4. Double minute (DM) inferred from whole-genome sequencing of circulating tumor DNA.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 4. Double minute (DM) inferred from whole-genome sequencing of circulating tumor DNA.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 2. Targeted and whole-genome sequencing (WGS) of metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 2. Targeted and whole-genome sequencing (WGS) of metastatic urothelial cancer (mUC) circulating tumor DNA (ctDNA).
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 1. Identification of ERBB2 mutations and copy number amplifications.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Figure 1. Identification of ERBB2 mutations and copy number amplifications.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 11. ERBB2 structural variants detected in whole-genome ctDNA sequencing.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 11. ERBB2 structural variants detected in whole-genome ctDNA sequencing.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 14. Agreement between ERBB2 genotype and HER2 IHC.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 14. Agreement between ERBB2 genotype and HER2 IHC.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 4. Mutation-based ctDNA fraction estimation. List of samples showing the mutation used for tumor fraction estimation.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
Supplementary Table 4. Mutation-based ctDNA fraction estimation. List of samples showing the mutation used for tumor fraction estimation.